Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis
Open Access
- 1 June 2007
- journal article
- research article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 5 (6), 1237-1242
- https://doi.org/10.1111/j.1538-7836.2007.02526.x
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Ximelagatran: An eulogyThrombosis Research, 2006
- The status of new anticoagulantsBritish Journal of Haematology, 2006
- Direct Thrombin InhibitorsNew England Journal of Medicine, 2005
- Systematic Overview of Warfarin and Its Drug and Food InteractionsArchives of Internal Medicine, 2005
- A new oral anticoagulant: the 50-year challengeNature Reviews Drug Discovery, 2004
- Oral direct thrombin inhibitors in clinical developmentJournal of Internal Medicine, 2003
- Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and SafetyChest, 2001
- Synthetic Inhibitors of Thrombin and Factor Xa: From Bench to BedsideThrombosis Research, 1999
- Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.Journal of Clinical Investigation, 1990
- Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy.Proceedings of the National Academy of Sciences, 1989